Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2020-06-11 Director's Dealing
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a person discharging managerial responsibilities ('Mark Müller', Member of the administrative or supervisory body). The structure follows standard regulatory disclosure formats for insider transactions, detailing the person, the reason, the issuer, and the specific transaction (Acquisition of Shares). This directly matches the definition for Director's Dealing.
2020-06-11 English
Xlife Sciences AG: The project company FUSE-AI GmbH reaches another milestone by developing ProstateCarcinoma.ai
Environmental & Social Information Classification · 1% confidence The document is titled 'News Details' and begins with a date and a headline about a project milestone ('Xlife Sciences AG: The project company FUSE-AI GmbH reaches another milestone...'). It is distributed via 'DGAP-Media' and explicitly states 'End of Media Release'. The content describes technological progress (AI development for cancer diagnosis) rather than financial results, board changes, or formal regulatory filings like 10-K or IR. This format strongly suggests a press release or general corporate news announcement. Since 'Press Release' is not a primary category, and it is not a specific financial report, management change, or shareholder action, the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a general category for official corporate announcements distributed via news services like DGAP/EQS.
2020-06-10 English
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
Regulatory Filings Classification · 1% confidence The document is a short announcement dated March 11, 2020, classified as 'Ad-hoc' and explicitly states it is a 'Disclosure of an inside information acc. to Article 17 MAR'. This type of immediate, material, non-periodic disclosure, often disseminated via services like DGAP (a service of EQS Group AG), does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER). It is a general regulatory announcement concerning company news (a potential COVID-19 therapy development). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for miscellaneous, non-standard regulatory disclosures that are not formal periodic reports or specific corporate actions like dividends or director dealings.
2020-03-11 English
Xlife Sciences AG: Capital Increase 'Private Placement'
Capital/Financing Update Classification · 1% confidence The document is an 'Ad-hoc' announcement dated February 14, 2020, titled 'Xlife Sciences AG: Capital Increase ‘Private Placement’'. It explicitly discusses the execution of a capital increase via a private placement of 260,000 shares. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the provided definitions, this aligns best with the 'Capital/Financing Update' category (Code: CAP). The document is short and is an announcement, but the content is specific enough to classify it beyond a general RPA or RNS.
2020-02-14 English
Xlife Sciences AG: New project in the portfolio
Regulatory Filings Classification · 1% confidence The document is titled 'News Details' and is explicitly identified as a 'DGAP-Media' release disseminated by EQS Group AG. It announces a new project ('clyxop devices') within the portfolio of Xlife Sciences AG, detailing the technology and the company's business model. This format—a brief announcement of corporate news, often related to R&D or business updates, distributed via a news service (DGAP)—does not fit the specific financial report categories (10-K, IR, ER, AR, etc.). Since it is a general corporate announcement that doesn't fit the other specific categories (like M&A, Director's Dealing, Dividend), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous news releases distributed through official channels.
2020-01-24 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Oliver R. Baumann), their position ('Member of the managing body'), the nature of the transaction ('Acquisition'), the financial instrument (Share), and the date and price of the transaction. This content directly matches the definition for Director's Dealing.
2020-01-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.